Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS
Go back to Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS| Entrx Corporation (NASDAQ: ENTX) | Delayed: 3.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $0.30 | |||
| Open | $3.05 | 52 Week Low | $0.10 | |||
| Day High | $3.05 | P/E | N/A | |||
| Day Low | $3.05 | EPS | $0.00 | |||
| Volume | 1,501 | |||||



